Table 5: Select Bone morphogenetic proteins: properties, indications and product examples.
Alternate Names | FDA Approved Indications | Osteoinductive Properties | Angiogenic Properties | Comments | Commercial Products | Price25 | |
---|---|---|---|---|---|---|---|
BMP-1 |
|
|
|
|
A metalloproteinase (only BMP not from TGF-β family). May induce cartilage formation in vivo26 |
|
|
BMP-2 |
|
Approved for ALIF and acute open tibia fracturesa |
+ |
+7 |
Only BMP to induce osteoblastic differentiation of MSCs7 |
Infuseb |
$3500-4900 |
BMP-3 |
|
|
|
|
No demonstrated osteoinductive activity |
|
|
BMP-4 |
|
|
+ |
|
Overexpressed in Fibrodysplasia Ossificans Progressiva27 |
|
|
BMP-6 |
|
|
+ |
|
May play a role in iron regulation through effect of iron regulatory hormone, hepcidin28 |
|
|
BMP-7 |
Human Osteogenic Protein-1 |
Approved (HDE only) for revision PLIF and long bone nonunionsc |
+ |
+7 |
|
OP-1d |
$5,000 |
BMP-14 | rhMP52, GDF-5, CDMP-120 | + | Animal models demonstrate equal or better efficacy than autograft in ALIF procedures. May play a role in embryonic limb differentiation.20 |
a ALIF, anterior lumbar interbody fusion; bInfuse (Medtronic Sofamor Danek); cHDE, humanitarian device exemption; PLIF, posterior lumbar interbody fusion; dHuman Osteogenic Protein-1 (OP-1, Stryker Biotech)